9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

Estimated reading time: < 1 min

Condition: Advanced Malignancies

Estimated Enrollment: 52

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Active, not recruiting

Study Results: No Results Available

Outcome Measures: Phase 1: Participants With Treatment-Emergent Adverse Events (TEAEs) [Safety and Tolerability],  Phase 2: Objective response rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1,  Phase 1 & Phase 2: ORR based on RECIST v1.1 and modified RECIST (mRECIST), Phase 1 & Phase 2: Duration of response based on RECIST v1.1 and mRECIST

Interventions: INCAGN01949, Nivolumab

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: August 2019

Completion Date: August 2019

Last  Posted Date: April 30, 2019

Location: The University of Alabama Birmingham (UAB), Birmingham, Alabama, United States

Website Link: https://ClinicalTrials.gov/show/NCT03241173

Was this article helpful?
Dislike 0